Technology | December 19, 2014

Volpara Solutions Launches VolparaDensity 3.0 for 2-D and 3-D Breast Density Assessment

Software suitable for use with digital mammography and digital breast tomosynthesis

Volpara, VolparaDensity, version 3.0, RSNA 2014

Image courtesy of Volpara Solutions

December 19, 2014 – Volpara Solutions announced the launch of the VolparaDensity version 3.0 breast density assessment tool at the 100th annual meeting of the Radiological Society of North America (RSNA), Nov. 30-Dec. 5 in Chicago. Available clinically for use with digital breast tomosynthesis datasets from multiple manufacturers, the system is already in use at Peninsula Diagnostic Imaging in San Mateo, Calif., and Santa Barbara Women’s Imaging in Santa Barbara, Calif. 

VolparaDensity for use with Hologic tomosynthesis systems will be available immediately and the new version for use with GE and Siemens tomosynthesis units will be available in early 2015.

A digital breast tomosynthesis exam, sometimes called a 3-D mammogram, is performed similarly to a traditional mammogram where the technologist compresses the breast and acquires images from different angles. Tomosynthesis is a multi-view mammography technique where each of the individual tomosynthesis projections acquired is a low dose, 2-D projection mammogram.

“We screen patients with dense breasts with 3-D tomosynthesis while women with fatty breasts continue to get conventional 2-D digital mammography because of the lower dose. We are excited to have the option of providing objective, volumetric breast density for all of our patients as the ability to provide consistent and accurate breast density values is critical to proper patient management. Breast density assessment should be the same no matter if the image was acquired using 2-D or 3-D.  It is, after all, the same breast, so it is very reassuring that VolparaDensity has been highly correlated between mammography and tomosynthesis,” said Susan Marks, M.D., director of breast imaging at Peninsula Diagnostic Imaging.

The VolparaDensity software, which has been in clinical use since 2010, was developed to be suitable for use with both digital mammography and digital breast tomosynthesis data from any manufacturer. It uses the same algorithm to process both the acquired tomosynthesis projections and the raw data of a conventional 2-D mammogram,  and also reduces the challenges of visually determining breast density based on a review of tomosynthesis slices and synthetic 2-D images (C-View from Hologic, V-Preview from GE) and enables consistent density assessments based on each patient’s actual breast tissue composition.

“Informing women about their breast density is critical to their ability to make informed decisions about their breast health. By providing reproducible and consistent volumetric density for 3-D tomosynthesis, VolparaDensity helps improve screening for women with dense breasts by enabling radiologists to more systematically determine which patients would benefit from supplemental imaging such as automated breast ultrasound,” said Judy Dean, M.D., senior radiologist, Santa Barbara Women’s Imaging.

VolparaDensity is in use at breast imaging centers worldwide to help radiologists objectively assess density from both digital mammography and tomosynthesis images and to determine which women would benefit from additional screening. Highly correlated to breast magnteic resonance (MR) assessments, VolparaDensity automatically generates an objective measurement of volumetric breast density correlated to the American College of Radiology (ACR) breast density categories.

For more information: www.volparasolutons.com

Related Content

Lunit Receives Korea MFDS Approval for Lunit Insight MMG
News | Artificial Intelligence | August 19, 2019
Lunit has announced Korea Ministry of Food and Drug Safety (MFDS) approval of its artificial intelligence (AI) solution...
Imago Systems Announces Collaboration With Mayo Clinic for Breast Imaging

Image courtesy of Imago Systems

News | Mammography | August 14, 2019
Image visualization company Imago Systems announced it has signed a know-how license with Mayo Clinic. The multi-year...
Artificial Intelligence Could Yield More Accurate Breast Cancer Diagnoses
News | Artificial Intelligence | August 13, 2019
University of California Los Angeles (UCLA) researchers have developed an artificial intelligence (AI) system that...
Lake Medical Imaging Selects Infinitt for Multi-site RIS/PACS
News | PACS | August 09, 2019
Infinitt North America will be implementing Infinitt RIS (radiology information system)/PACS (picture archiving and...
Volpara to Distribute Screenpoint Medical's Transpara AI Solution
News | Breast Imaging | August 02, 2019
Volpara Solutions and ScreenPoint Medical BV signed an agreement under which Volpara will sell ScreenPoint's Transpara...
Ikonopedia Releases Automated Combined Reporting Package at AHRA
News | Mammography Reporting Software | July 26, 2019
Ikonopedia showcased its recently released Automated Combined Reporting package and its entire suite of structured...
Hologic Partners With MagView to Develop Unifi EQUIP Solution
Technology | Mammography Reporting Software | July 25, 2019
Hologic announced a partnership with mammography information solutions provider MagView to develop Unifi EQUIP, an...
Fujifilm Releases Tomosynthesis Biopsy Option for Aspire Cristalle Mammography System
Technology | Breast Biopsy Systems | July 24, 2019
Fujifilm Medical Systems U.S.A. Inc. recently expanded its breast imaging solutions with the launch of its...
IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017.

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017, and who had health records for at least one year prior to the mammogram. The algorithm was trained on 9,611 mammograms. Image courtesy of Radiology.

Feature | Artificial Intelligence | July 19, 2019 | Michal Chorev
Breast cancer is the global leading cause of cancer-related deaths in women, and the most commonly diagnosed cancer...
Paragon Biosciences Launches Qlarity Imaging to Advance FDA-cleared AI Breast Cancer Diagnosis System

Qlarity Imaging’s software is used to assist radiologists in the assessment and characterization of breast lesions. Imaging features are synthesized by an artificial intelligence algorithm into a single value, the QI score, which is analyzed relative to a database of reference abnormalities with known ground truth. Image courtesy of Business Wire.

Technology | Artificial Intelligence | July 18, 2019
Paragon Biosciences LLC announced the launch of its seventh portfolio company, Qlarity Imaging LLC, which was founded...